Lenalidomide for MDS: Treatment, Uses, and Side Effects

Lenalidomide is an oral immunomodulatory drug approved by the U.S. FDA specifically for lower-risk myelodysplastic syndromes (MDS) that carry a deletion on chromosome 5q, a genetic change found in roughly a quarter of MDS patients.¹ It works by selectively destroying a protein that the del(5q) clone depends on for survival, and in doing so it can free many patients from the chronic red-blood-cell transfusions that define their daily life. The drug’s story in MDS is one of genuine success tempered by real side effects and lingering questions about long-term safety, and all of those threads matter if you or someone you know is weighing treatment.

How Lenalidomide Works in Del(5q) MDS

MDS with a 5q deletion means that one copy of a stretch of chromosome 5 is missing in the abnormal blood-forming cells. Among the genes lost in that deleted region is one encoding a protein called casein kinase 1 alpha (CK1α). Because only one copy of the gene remains, these cells are already making less CK1α than healthy cells. Lenalidomide exploits that vulnerability. It binds to a protein called cereblon, which is part of the cell’s protein-disposal machinery, and redirects that machinery to tag CK1α for destruction.² In normal cells with two working copies of the gene, losing some CK1α is tolerable. In del(5q) cells that already have only half the usual amount, the additional loss tips them over the edge, triggering a self-destruct signal. Researchers describe this as “synthetic lethality”: the drug alone is not lethal, and the deletion alone is not lethal, but together they specifically kill the abnormal clone while sparing most healthy blood-forming cells.³

That selectivity is what makes lenalidomide so effective in del(5q) MDS compared with more blunt chemotherapy approaches. By clearing the abnormal clone, normal red blood cell production can resume, which is why many patients become transfusion-independent within a few months of starting treatment.

How Well It Works

The landmark trial that led to FDA approval enrolled patients with lower-risk del(5q) MDS who depended on regular blood transfusions. Among the 85 patients whose chromosomes could be evaluated, 62 showed cytogenetic improvement, meaning the del(5q) clone shrank. Of those 62, 38 achieved a complete cytogenetic remission, with no detectable abnormal cells in the bone marrow.⁴ These numbers were striking for a disease that previously had few effective drug options.

Early trials consistently showed rapid and durable responses, and a subsequent large phase III trial confirmed the pattern.⁵ For many patients, the practical outcome is months or years without transfusion visits, which translates to meaningful quality-of-life gains. In clinical studies, patients who achieved at least eight weeks of transfusion independence showed significant improvements across multiple quality-of-life measures, including physical function, fatigue, and overall well-being.⁶ Those improvements were sustained at follow-up assessments out to 48 weeks in del(5q) patients who maintained transfusion freedom.⁷

Common Side Effects

The most frequent and clinically significant side effect of lenalidomide in MDS is, paradoxically, lowered blood counts. Patients already have impaired bone marrow function from MDS, and as lenalidomide kills the abnormal clone, blood counts can temporarily get worse before they get better. Low platelets (thrombocytopenia) and low white blood cells (neutropenia) are common, especially in the first few weeks. In a well-documented case, a patient developed drops across all three blood cell lines within the first three weeks of treatment. Lenalidomide was paused for about three weeks to allow recovery, then restarted at a dose of 10 mg daily. Over an 11-year treatment period, this patient’s average platelet count stayed below normal, and white blood cell counts remained slightly low as well.⁸ That pattern is representative: many patients tolerate the drug long-term but live with blood counts that sit below the normal range.

Beyond blood counts, other side effects include:

Blood clots: Venous thrombotic events occurred in about 17% of lenalidomide-treated MDS patients in one study, with all events happening after a year of treatment, suggesting the risk grows with prolonged use.⁹
Gastrointestinal symptoms: Diarrhea, nausea, and constipation are common but usually manageable.
Skin reactions: Rash and itching occur in a notable minority of patients, sometimes requiring dose adjustment.
Fatigue: Though many patients paradoxically feel better as their anemia improves, some experience treatment-related fatigue independent of hemoglobin changes.

Blood clot risk is worth paying particular attention to because it can be serious. Some clinicians prescribe low-dose aspirin or other preventive measures, especially for patients with additional clot risk factors. Regular monitoring of blood counts, typically every one to two weeks at the start, is standard practice to catch cytopenias early.

Pregnancy Risk and the REMS Program

Lenalidomide is structurally related to thalidomide, the notorious drug that caused severe birth defects in the 1950s and 1960s. Lenalidomide carries the same teratogenic risk. Because of this, the drug is available in the United States only through a restricted distribution program called a Risk Evaluation and Mitigation Strategy (REMS). The program requires patients, prescribers, and pharmacies to register and follow strict rules. Women of childbearing potential must use two forms of contraception and undergo regular pregnancy testing. Men must also use contraception because lenalidomide is present in semen. Survey data show the education effort works: over 98% of patients enrolled in the REMS program knew that the drug could cause birth defects.¹⁰ Because the average age of MDS diagnosis is in the late 60s to 70s, most patients are past reproductive age, but the rules apply regardless.

Does Lenalidomide Increase the Risk of Leukemia?

This question has hung over lenalidomide in MDS since early in its development. Lower-risk MDS can progress to acute myeloid leukemia (AML) even without treatment, and some clinicians worried that lenalidomide might accelerate that progression. The evidence accumulated over the past decade is mostly reassuring. A French comparative study found that at four years, the estimated rate of leukemia was 9% in lenalidomide-treated patients versus about 16% in untreated controls, a difference that was not statistically significant.¹¹ A separate multivariate analysis looking at five-year outcomes found AML progression rates of 31% in lenalidomide-treated patients and 25% in untreated patients, but again the difference was not statistically significant after adjusting for other risk factors.¹²

A systematic review and meta-analysis that pooled data across lenalidomide trials in MDS and other blood cancers found no increased risk of second primary cancers in MDS patients receiving the drug.¹³ The overall picture is that lenalidomide does not appear to push patients toward leukemia at a rate above what the underlying disease already carries.

When Patients Respond, Outcomes Improve

A pattern that emerges repeatedly across lenalidomide studies is that the benefit tracks closely with response. Patients who achieve and maintain transfusion independence survive longer and have a lower risk of AML progression compared with those who do not respond. In one long-term analysis, transfusion independence lasting at least eight weeks was independently associated with longer survival, and cytogenetic response correlated with a reduced risk of progression to AML.¹⁴

Conversely, patients who do not achieve a sustained response face a steeper trajectory. In one cohort followed for a median of 40 months, about 36% progressed to AML. Among those who did progress, 87% had acquired additional chromosome changes beyond the original 5q deletion. Patients who had achieved a cytogenetic response had a five-year AML risk of about 21%, while those without cytogenetic response had a five-year risk of roughly 60%.¹⁵ The message for patients and clinicians is that early response assessment matters: if lenalidomide is working, it tends to protect; if it is not, alternative strategies should be considered sooner rather than later.

Dose Management and Why It Matters

The standard starting dose for del(5q) MDS is 10 mg daily, taken on days 1 through 21 of a 28-day cycle, though some patients start on a continuous daily schedule. Because cytopenias are so common early on, dose reductions and treatment interruptions are a routine part of managing therapy. Far from being a treatment failure, these adjustments are associated with better long-term outcomes. A large database analysis found that patients who required dose modifications actually had longer treatment durations and longer follow-up, suggesting that staying on therapy, even at a reduced dose, is more important than rigidly maintaining the original dose.¹⁶ Some clinicians have explored alternate-day dosing schedules for patients who struggle with daily dosing side effects, with reports of improved tolerability.¹⁷

For patients with significant kidney problems, dose adjustment is essential because lenalidomide is cleared primarily through the kidneys. Studies have confirmed that reduced doses can be safe and effective in patients with severe renal impairment.¹⁸ Your treatment team will typically calculate the appropriate dose based on kidney function tests.

The TP53 Problem and Resistance

Not everyone responds to lenalidomide, and some who initially respond eventually lose that response. One major reason involves the TP53 gene, which produces the protein p53, often called the “guardian of the genome” because it helps cells self-destruct when they become damaged. Lenalidomide’s mechanism of killing del(5q) cells works through p53: once CK1α is degraded, the resulting signal triggers p53-dependent cell death. This means that cells carrying TP53 mutations, which disable that self-destruct pathway, are inherently resistant to lenalidomide.

The concern goes further. Research has shown that lenalidomide treatment can actively select for TP53-mutant cells. In laboratory experiments, lenalidomide, but not the related drug pomalidomide, led to the outgrowth of TP53-mutant blood-forming stem cells across all cell lineages. In patient data, TP53 mutations were significantly associated with prior treatment using thalidomide-type drugs, with lenalidomide accounting for 92% of that exposure. The statistical association was strong, with the odds of finding a TP53 mutation roughly three times higher in patients previously treated with these drugs.¹⁹ This does not mean lenalidomide causes TP53 mutations from scratch. Rather, tiny populations of TP53-mutant cells that may already exist in the bone marrow gain a survival advantage when the drug eliminates their competitors. Over time, those resistant cells can expand and potentially drive disease progression.

This finding has influenced how clinicians approach monitoring. Some centers now test for TP53 mutations before starting lenalidomide and at intervals during treatment, aiming to catch expansion of resistant clones early. Identifying a growing TP53-mutant population might prompt a shift to a different treatment strategy.

Using Lenalidomide Beyond Del(5q) MDS

Although the FDA approval is specifically for lower-risk MDS with a 5q deletion, clinicians and researchers have explored lenalidomide in MDS patients who lack that specific genetic change. The responses in non-del(5q) lower-risk MDS are generally more modest. Early data from a combination trial of lenalidomide with luspatercept (a drug that promotes red blood cell maturation through a different pathway) in non-del(5q) lower-risk MDS patients showed that about half of evaluable patients achieved some form of blood-count improvement, though transfusion independence was reached by only about 30%.²⁰

Lenalidomide has also been studied in combination with azacitidine, a hypomethylating agent, for higher-risk MDS. In a phase 2 trial, this combination produced an overall response rate of 72%, with 44% of patients achieving a complete response. Those numbers were encouraging enough to generate further investigation, though the combination also carried higher rates of cytopenias than either drug alone.²¹ These expanded uses remain an active area of research rather than established standard care for most patients.

Cost and Access

Lenalidomide is not cheap. In the United States, a cost-effectiveness analysis estimated one-year total treatment costs at roughly $63,000, compared with about $55,000 for best supportive care (essentially transfusions plus supportive medications). The higher drug cost was partly offset by savings from fewer transfusions and reduced use of erythropoietin, a hormone injection sometimes given to boost red blood cell production. The incremental cost was estimated at about $35,000 per quality-adjusted life-year gained, a figure considered within the acceptable range for new therapies in the U.S. health system.²²

In the United Kingdom, a real-world evidence analysis found that lenalidomide was cost-effective at the country’s standard threshold, with most of the benefit coming from extended time spent free from transfusions. Savings from reduced iron chelation therapy and fewer transfusion units together offset a substantial portion of the drug cost, amounting to combined savings of roughly £26,000 over a patient’s lifetime.²³ Those numbers matter because in many health systems, proving cost-effectiveness is what determines whether a drug is available to patients through public insurance. Despite these favorable analyses, out-of-pocket costs can still be significant depending on your insurance. Patient assistance programs from the manufacturer exist, and your treatment team can usually help navigate them.

What Iron Overload Has to Do With It

Patients who need regular red blood cell transfusions accumulate excess iron over time, because the body has no efficient way to get rid of extra iron once it enters the bloodstream. Iron overload can damage the heart, liver, and endocrine organs. Patients on chronic transfusion often require iron chelation therapy, which involves taking drugs that bind iron so the body can excrete it. These chelation drugs have their own side effects and add to treatment burden and cost.

One of the under-appreciated benefits of lenalidomide for transfusion-dependent del(5q) MDS patients is that achieving transfusion independence halts the progressive iron loading. Patients who respond well to lenalidomide not only feel better from improved hemoglobin levels but also stop accumulating the organ damage associated with iron overload. Over years of follow-up, the reduced need for chelation contributes meaningfully to both quality of life and cost savings, as captured in the economic analyses that factor chelation avoidance into lenalidomide’s overall value.